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Dear Readers
Hope you all had a great summer.

program and we hope you will be a part of it.

Year 2017s second issue of LABRAD is in your
hands! This time it is non-thematic and has some
useful articles like the broad clinical applications
of platelet-rich plasma, clinical utility of plasma
homocysteine, diagnostic tests available for
Alkaptonuria and a discussion on soft tissue lesions.
Another interesting article which might interest
the pathologists is ‘Patient Based Quality Control:
Hitting a Moving Target’ which discusses patient
based QC procedures and how patient results can
be utilized to monitor an analytical run and identify
systematic errors.

The Department of Pathology and Laboratory
Medicine is committed to providing high
quality diagnostic services for physicians across
Pakistan. One of the goals of the Department is
to update physicians throughout Pakistan about
the advancement in laboratory sciences and the
services available at the Clinical Laboratory, through
Continuing Medical Education (CME) lectures
across the country, laboratory updates and LABRAD.
In order to keep the contents of LABRAD current
and dynamic, readers are encouraged to send
short articles on topics pertinent to healthcare and
laboratories today. Since last year LABRAD is
marked in the Institutional Repository and available
on http://ecommons.aku.edu/pakistan. Readers from
outside Aga Khan University now have the access
current and previous issues of LABRAD from here
and this has improved our newsletter readership.
I hope you enjoy this issue.
Happy reading.

Just to inform you all the 40th Annual Pakistan
Association of Pathologists (PAP) Conference will
be held from 14th to 16th December 2017 at Sindh
Institute of Urology and Transplantation (SIUT),
Karachi, Pakistan. The program will include preconference workshops, state of the art lectures by
local and foreign faculty, plenary sessions, oral and
poster presentations. The local organizers are already
hard at work putting together an exciting scientific

Lena

Clinical Applications of Platelet-Rich Plasma
Dr Anila Rashid
Haematology & Transfusion Medicine

Platelet-rich plasma (PRP) is an autologous
product derived from whole blood through
the process of gradient density centrifugation.
PRP functions as a fibrin tissue adhesive with
hemostatic and tissue sealing properties, but it
differs from fibrin glue and other platelet-poor
tissue adhesives because its platelets provide a
unique ability to promote wound healing and
enhance osteogenesis. PRP provides an immediate
surgical hemostatic agent that is biocompatible,
safe, and effective. PRP accelerates endothelial,
epithelial, and epidermal regeneration, stimulates
angiogenesis, enhances collagen synthesis,
promotes soft tissue healing, decreases dermal
scarring, enhances the hemostatic response to
injury, and reverses the inhibition of wound

healing caused by glucocorticoids. The high
leukocyte concentration of PRP has an added
antimicrobial effect. Since PRP is an autologous
blood product, it carries no risk of transmitting
infectious disease.
PRP has an extremely broad range of clinical
healing applications in head and neck surgery,
otolaryngology, cardiovascular surgery, burns and
wound healing, oral and maxillofacial surgery,
cosmetic surgery, and periodontics (Table 1).
In addition to its effectiveness for patients with
chronic non-healing wounds, it has also been used
as an antiangiogenic agent and as a carrier for
growth factors.
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Preparation
Numerous techniques have been described for the
immediate preoperative preparation of autologous
PRP, but most are variations on a standard theme.
Blood is drawn from the patient and fractionated
using centrifugation. The platelets are concentrated
in the platelet rich plasma at levels generally six to
eight times the baseline levels. The resultant PRP is
stored at room temperature until needed, at which
time 10,000 units of powdered bovine thrombin is
mixed with 10 percent calcium chloride. Next, the
PRP is drawn into a 10ml syringe. The thrombin/
calciumchloride mixture then is aspirated into a
one ml syringe and both syringes are mounted in a
mixing applicator. At the tip of the applicator, the
two preparations are mixed to activate the PRP.
Within five to 30 seconds, a gel is formed as the
citrate is neutralized and the thrombin activates
polymerization of the fibrin and degranulation of the
platelets. The gel is then inserted into the surgical
field as needed.
Most current methods of PRP preparation use
calcium and bovine thrombin to initiate formation
of PRP gel. The use of bovine thrombin has
unfortunately been associated with the development
of antibodies to human clotting factors V, XI, and
thrombin, resulting in a risk of potentially lifethreatening coagulopathies. Several commercial
systems are available for preparing PRP, including
the Cobe Angel Whole Blood Separation System
which also can produce fibrin glue (Cobe
Cardiovascular, Inc., Arvada, Colorado) and the
Sequire Platelet Concentrating System (PPAI
Medical, Fort Myers, Florida). Most commercial
PRP preparation systems are available for offi ce use
by dental practitioners, podiatrists and wound care

physicians. In comparison with previous methods
that employed autotransfusion devices, current
automated systems have shorter preparation times
and require substantially less blood volume.
Contraindications
Treatment with autologous PRP is generally
considered safe in appropriately selected patients.
Potential candidates for treatment with PRP should
undergo a pretreatment hematologic evaluation
to rule out potential coagulopathies and disorders
of platelet function. Patients who are anemic and
those with thrombocytopenia may be unsuitable
candidates for treatment with PRP. Other potential
contraindications include hemodynamic instability,
severe hypovolemia, unstable angina, sepsis, and
anticoagulant or fibrinolytic drug therapy.
Conclusion
Autologous PRP is a relatively new biotechnology
that has shown promise in the stimulation and
acceleration of soft-tissue and bone healing. The
application of PRP has been extended to many
different fields, including orthopedics, sports injuries,
dental and periodontal surgery, and cosmetic, plastic,
cardiovascular, general and maxillofacial surgery.
Few well-designed scientific studies of the clinical
use of PRP are available. The exact mechanisms of
action of the many components of PRP are not fully
understood, and the ideal ratios of these components
are unknown. In some circumstances, the cost of
implementing this promising technology must be
weighed against its benefits, and well-designed
controlled clinical studies are needed to provide clear
evidence of the capacity of PRP to improve patient
outcomes.

Table I: Clinical Applications of Platelet-Rich Plasma

Cosmetic Surgery

Otorhinolaryngology-Head and Neck Surgery

Full and split-thickness skin grafts donor sites and recipient sites
Skin flaps
Bone grafts
Metal implants
Tissue expansion
Aesthetic Surgery (Face Lifts, liposuction, etc)

Radical neck dissections
Pectoralis major myocutaneous flaps
Facial fractures
Reconstructions

Oral and Maxillofacial Surgery

Neurosurgery

Mandibular reconstruction
Alveolar cleft repair
Oral-nasal fistulas

Pituitary tumor removal
Skull base tumor resection
Intradural procedures involving tumor or release of tethered cords
Dural tumors Acoustic neuroma excisions (dura tears during laminectomy)

4
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Orthopedic/Spinal Surgery

Cardiothoracic Surgery

Total Hip Replacement
Total Knee Replacement
Scoliosis Repair
Spinal Fusion
All Open and Internal Reduction Fixation Operations
Hand and Foot Surgery Bone Graft Surgery

Sternotomy Graft Conduit Sites
Esophagogastrectomy

Eye-PRP
treatment of dormant ulcers (epithelial defects of the cornea that
fail to heal)
dry eye syndrome
ocular surface syndrome post Laser In Situ Keratomileusis
(LASIK)
Surface reconstruction after corneal perforation associated with
amniotic membrane transplantation.
Periodontal Surgery

General Surgery

Dental implants
Guided Bone Regeneration

Recurrent Hernia Repair
Anal Fistula
Bariatric Surgery

Rota Virus: Diagnosis & Prevention of
Infection
Ms Syeda Kiran Zaidi
Clinical Microbiology

Rotavirus is the cause of mild to severe diarrhea in
more than 18 million children under five years of age
and is responsible for approximately 873,000 deaths
per year. Due to compromised sanitation amenities
and medical facilities available in the developing
world, there is increased transmission and poor
access to rehydration in patients suffering from
severe vomiting and diarrhea due to rotavirus. It is
also an important cause of nosocomial diarrhea.
Transmission and Reservoirs
Rotavirus is transmitted primarily through the fecaloral route, meaning an infected person must shed
the virus through their stool and then a susceptible
person must ingest it in order to cause an infection.
Because rotaviruses grow and multiply in the
intestinal villi, the gastrointestinal tract and stool
serve as the reservoirs for rotavirus in infected
humans.
Signs and Symptoms
The most common symptoms include abdominal

pain, vomiting, fever, and diarrhea. However,
in some individuals rotavirus may also be
asymptomatic. Although infants under three months
of age may be infected, generally the first infection
after three months is the most severe.
Diagnosis
The name rotavirus is derived from the Latin word
“rota”, meaning “wheel”. Rotaviruses belong to the
family Reoviridae and are nonenveloped, doubleshelled RNA viruses. The genome codes for six
structural and six nonstructural proteins. The virus is
stable in the environment.
Laboratory diagnosis of rotavirus infection is usually
performed by antigen detection, using enzyme
immunoassay or latex agglutination techniques,
which have a sensitivity and specificity above 90 per
cent. Molecular techniques such as polyacrylamide
gel electrophoresis (PAGE) and reverse transcriptionpolymerase chain reaction (RT-PCR) are used
to determine the RNA migration patterns and
virus genotyping, respectively. The advantage of
confirming a case of rotavirus diarrhoea
5
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stool specimens is 1.8-3.7x108 rotavirus particles
per test volume. The assay is not recommended
on meconium (early neonatal) stools as their
performance characteristics have not been evaluated.
A positive result does not preclude the presence of
other infective organisms.
Prevention/Vaccines

Rota Virus: Electron microscopy (courtesy Google Images)

by laboratory testing is primarily epidemiological
so that preventive measures may be initiated for the
community at risk.
We, at Aga Khan University Hospital (AKUH) will
be starting Rotavirus detection by Immuno Card
STAT Rotavirus assay® (Meridian Bioscience, USA)
which detects the presence of rotavirus antigen in
stool through monoclonal antibodies directed against
simian rotavirus strain (SA-11). It has specificity of
95.8 per cent and sensitivity of 93.1 per cent and it
gives result in just 10 minutes. Limit of detection in

Rotavirus is susceptible to strong disinfectants such
as formalin and 95 per cent ethanol. Washing hands
is not enough in preventing a rotavirus infection, as
the viruses are relatively resistant to soap and water.
Currently there are two FDA approved vaccinations
for rotavirus. RotaTeq was approved in 2006,
and two years later in April of 2008 Rotarix was
approved. Both vaccines are live attenuated viral
vaccines taken orally in a scheduled series. RotaTeq
is given in a three dose series at two, four, and six
months of age, whereas Rotarix is given in a two
dose series at four and six months. Studies report an
85-98 per cent efficacy rate against severe rotavirus
infection, and a 74-87 per cent efficacy rate against
rotavirus infection of any severity.

Anti-Musk Antibodies for Seronegative
Myasthenia Gravis
Dr Syed Bilal Hashmi
Chemical Pathology

Myasthenia gravis is the most common disorder of
neuromuscular transmission. It can present at any
age, but there tends to be a bimodal distribution to
the age of onset with an early peak in the second
and third decades with female predominance
and a late peak in the sixth to eighth decade with
male predominance. This autoimmune disease is
caused by autoantibodies directed against muscle’s
nicotinic acetylcholine receptor (AChRs) or musclespecific receptor tyrosine kinase (musk). There are
two clinical forms of myasthenia gravis, ocular
and generalized. In neonates, a transient form of
myasthenia, called neonatal myasthenia gravis, can
occur as a result of the trans placental passage of
maternal antibodies that interfere with function of
the neuromuscular junction but symptoms disappear
after few weeks.

fluctuating skeletal muscle weakness, in any
skeletal muscle group. The weakness may fluctuate
throughout the day, but it is most commonly worse
later in the day or evening. More than 50 per cent
of patients present with ocular symptoms of ptosis
or diplopia while 15 per cent of patients present
with bulbar symptoms like dysarthria, dysphagia
and fatigable chewing. Less common presentations
include isolated neck weakness, isolated respiratory
muscle weakness, and distal limb weakness.

The cardinal feature of myasthenia gravis is

Anti- acetylcholine antibodies are used as a first

6

The diagnostic approach to myasthenia is focused
on confirming the clinical diagnosis established
by the history and typical examination findings.
More reliable laboratory methods that aid in the
confirmation are serologic tests for autoantibodies
and electrophysiologic studies.
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line test to diagnosis myasthenia gravis and for
distinguishing acquired disease (90 per cent
positive) from congenital disease (negative). They
are also used for monitoring disease progression
or response to immunotherapy. The antibodies
are present in 80-90 per cent of patients with
myasthenia gravis.
Anti- musk antibodies are used for diagnosis of
autoimmune myasthenia gravis in patients with new
onset acquired myasthenia gravis evident clinically
and electrophysiological but negative first-line
serological tests, i.e. autoantibodies against
AChRs. These autoantibodies are present in half
of seronegative myasthenia gravis patients. It also
helps in distinguishing autoimmune from congenital

myasthenia gravis, diagnosing ocular myasthenia
gravis and monitoring clinical course and response
to immunomodulatory treatment of a myasthenia
gravis patient.
The diagnosis of myasthenia gravis
in immunosuppressed or patients on
immunosuppressive drugs should be made with
caution because these autoantibodies may be falsely
low in such cases. Also 10 per cent of patients with
acquired, presumably immune-mediated myasthenia
gravis do not have detectable serum autoantibodies
to AChR or MuSK. In these seronegative patients,
the diagnosis is based on the clinical presentation,
the response to cholinesterase inhibitors and
electrophysiological findings.

Clinical Utility of Plasma Homocysteine
Salima Ratani and Hafsa Majid
Microbiology and Chemical Pathology

Role of Homocysteine in Atherosclerosis
Atherosclerosis is a pathologic process caused by
the buildup of plaque/ fatty material on the inside
of blood vessels leading to decreased blood flow
commonly affecting the coronary, cerebral and
peripheral arteries. Recently, there is increased
evidence that raised homocysteine levels in blood
are an independent cause of atherosclerotic vascular
disease and recurrent venous thromboembolism.
Homocysteine is an intermediary amino acid
produced during the conversion of methionine to
cysteine (Figure 1). Homocysteine has primary

atherogenic and prothrombotic properties.
Homocysteine-induced vascular injury include
intimal thickening, elastic lamina disruption, smooth
muscle hypertrophy, marked platelet accumulation,
and the formation of platelet-enriched occlusive
thrombi. Homocysteine causes vascular injury by
following mechanisms:
l
Increased leukocyte recruitment
l
increased smooth muscle proliferation and 		
collagen synthesis
l
attenuation of endothelial cell tissue
plasminogen activator binding sites
l
activation of factor VIIa and V
l
inhibition of protein C and heparin sulfate
l
increased blood viscosity, and decreased
endothelial antithrombotic activity due to
changes in thrombomodulin function
l
increased oxidative stress via production of free
radicals
l
increased platelet accumulation
l
decreased Nitric oxide production leading to
impaired endothelial vasodilation.
Causes of Hyperhomocytenemia
An inadequate intake of B vitamins, as well as
genetic factors that affect the body’s absorption and
use of folic acid, can lead to elevated homocysteine
levels. Homocysteine can be elevated in the
7
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following conditions:
Thermolabile variant of MTHFR (Methylene
Tetra Hydrofolate Reductase) having low
enzyme activity
l
Intracellular cobalamin defects
l
Vitamin B6 deficiency
l
Vitamin B12 deficiency
l
Folic acid deficiency
Plasma and urine concentrations of homocysteine
are severely elevated in a rare autosomal
recessive disorder; homocysteinuria or severe
hyperhomocytenemia. It is clinically manifested
as developmental delay, ocular abnormalities,
thromboembolic disease and even osteoporosis.
l

Laboratory Diagnosis
75 to 85 per cent of homocysteine is protein bound,
15 to 25 per cent is acid-soluble free forms. Plasma
homocysteine levels normally are between 5-12
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µmol/L and levels >100 µmol/L are considered
as severely high. An oral methionine challenge
(100 mg/kg) can be given to patients suspected of
hyperhomocysteinemia who have normal fasting
homocysteine levels. It is more useful for patients
with cystathionine-beta-synthase deficiency than
for those with MTHFR reductase deficiency. The
homocysteine concentration is measured on fasting
plasma samples before the methionine challenge
and four and eight hours afterward. The prognostic
significance of the oral methionine challenge is
uncertain. Correcting nutritional inadequacies will
lower homocysteine levels. A diet rich in fruits,
vegetables, and low-fat dairy products and low in
saturated and total fat also can lower fasting serum
homocysteine levels. Trials in primary and secondary
prevention of the disease show that adequate intake
of vitamin B complex, whether in diet or from
supplements, prevents homocysteine-associated
vascular disease.

Patient Based Quality Control: Hitting a
Moving Target
Dr Hafsa Majid
Chemical Pathology

Clinical laboratories are required to ensure accuracy
of every result reported; for that purpose since long
quality control materials are used. The CLIA have
recommended that minimum two level controls should
be run each day. The question arises whether with
increasing volumes this frequency of running controls
would be enough for high volume laboratories? On
the other hand if the controls run per day are increased
it will directly impact the cost. As a solution patients’
data can be utilized (‘patient-based quality control’)
that monitors in real time the average patient value for
any given analyte. The patients’ data can be used in two
ways for assessing systemic errors described below.
Average of Normals’ (AON)
The AON method of quality control was first
described by Hoffman & Waid in 1965. In AON,
an error condition is signaled in an analytic process
whenever the average of selected consecutive
patient data is beyond the control limits established
for the average of the patient population. Patient
results included if they were within a “normal
8

range” that was determined from patient data. For
control limits, Hoffman and Waid used the 95 per
cent confidence limits for the stable patient mean.
The AON can be done on relatively small sample
like significant analytic error could be detected by
averaging as few as ten consecutive values.
For establishing AON the laboratory needs to decide,
outliers to be excluded (especially for average), age
limits (eg 18 to 70yrs for serum creatinine), define
location of sample received from (eg dialysis unit,
surgical unit, outpatients etc) and if multiple results per
patient would be allowed or only one result per patient
will be taken
in calculation
of averages.
An example
of AON graph
for plasma
glucose is
shown in
figure 1.

Figure 1: Inpatients’ Average of Normal chart for plasma glucose for the
month of December.
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Patient Moving Averages (PMA)
Moving averages is a simple arithmetic mean of
predefined consecutive patient results. The number
of consecutive results to be included are decided,
average calculated and with each new patient result
the window moves by one patient result while
the oldest value drops out of view. The mean is
recalculated and data point plotted on a LeveyJennings chart.
In PMA calculation protocol two parameters need to
be defined:
a. The size of the error you wish to detect 		
		 require control limits and n (number of
		 consecutive results that need to be averaged).
		To detect
		 i. Large error; wider limits and large ‘n’
		 ii. Even a small error; narrow limits and
			 small ‘n’. Also It is easier to detect a
			 small shift for analytes that have a
			 narrow range (Na, Cl), than for highly
			variable analytes (Triglycerides)
b. Truncation limits: values that need to be 		
		 excluded from the mean calculation, eg days
		 when patient mix or volumes changes
		 drastically like on weekend patients’
		 volumes decrease so it can affect PMA of
		 that day and if multiple samples are received
		 from a camp for chronic kidney disease or
		 hepatitis C patients can affect PMA for
		 creatinine of LFTS. Such results should be
		 excluded from calculations.

In monitoring AON or PMA the goal is to monitor
the process and not the patients. In the absence of
systematic error, the mean patient value doesn’t
deviate significantly from the historic patient mean.
A mean exceeding predefined control limits thus
indicates the possible presence of a systematic error.
These tools are more useful when data is collected
regularly (every week or every month), and for
relatively high-volume tests (n=>50 samples per
day).
Selection of Analytes for PMA Monitoring
Not every analyte is amenable to PMA monitoring.
If daily test volume are less than the pre-decided
‘n’ for PMA calculation then there is no point in
monitoring PMA. It is not suitable for analytes
with great variability eg CK, LD. The PMA
monitoring will not be effective for analytes such
as troponin, as it is undetectable in most patients
so for it monitoring moving median will be more
practical.
Advantages of PMA Monitoring
Appropriately designed and implemented moving
averages protocols can detect a systematic error
hours before your next quality control run and will
also decrease the frequency of control runs per day.
The real challenge in setting up moving averages
monitoring is defining your own protocol and taking
corrective action to control the systematic error
identified.

Diagnosing Alkaptonuria: A Rare Inherited
Metabolic Disease
Dr Yusra Zaidi
Chemical Pathology

Alkaptonuria is a rare inherited metabolic disorder
(IMD) due to deficiency of the hepatic enzyme
Homogentisate 1,2-dioxygenase involved in tyrosine
degradation pathway forming an intermediate
metabolite homogentisic acid (HGA) and its
oxidative products in various connective tissue. The
true incidence of Alkaptonuria varies from 1:500,000
to 25:500,000, prevalence is higher in Middle
Eastern and Asian countries compared to western
countries owing to the high cousin marriage rate.

Life expectancy is not affected in patients with
Alkaptonuria, but the quality of life is significant
affected due to accumulation of HGA in the
tissues giving rise to ochronosis (yellow to brown
discoloration) in tissues especially cartilage, tendons,
ligaments, at times even bone and makes them
brittle, weak and susceptible to rupture.
Affected individuals may have dark urine or urine
that turns black when exposed to air. However,
9
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this change may not occur for several hours after
urination and often goes unnoticed. Most common
symptomatic presentation is arthritis especially in
the spine and large joints (Ochronotic arthropathy),
beginning early and progressing more rapidly in
males than females. Additional symptoms that
are seen less often include kidney stones, prostate
stones and heart disease due to accumulation of
HGA within the aortic or mitral valve.

Figure 1: Chromatogram showing Homogentisic Acid Peak (marked with
red arrow).
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Patients are diagnosed with Alkaptonuria based on
increased HGA excretion, evident by presence of
peak on urine organic acid chromatogram detected
by gas chromatography-mass spectrometry
analysis; as shown in figure 1. From 2013 till to
date the Biochemical Genetics Laboratory of our
section has reported nine cases of Alkaptonuria.
All patients were diagnosed based on marked
peaks of Homogentisic acid on urine organic
acid. Male to female ratio was 2:1. Most common
age of presentation was in third, fourth and fifth
decade of life while two cases presented within
first year of their birth.
Standard Treatment for Alkaptonuria includes
symptomatic treatment for pain using antiinflammatory drugs or narcotics may also be
prescribed, if needed. Dietary protein restrictions
are advised and vitamin C is prescribed,
which prevent accumulation and deposition
of HGA. Recently a drug, Nitisone is (a drug
for Tyrosinemia) is under study for use in
Alkaptonuria. It is shown to prevent significant
accumulation of homogentisic acid but further
research is needed to understand its safety and
effectiveness in long term usage.

Recently Described Soft Tissue Lesions: An
Update
Qurratulain Chundriger and Nasir Ud Din
Histopathology

Soft tissue pathology is a rapidly changing
subspecialty. Several soft tissue lesions have been
recently described in the medical literature. Some
are recently recognized, hence often underdiagnosed
because of limited knowledge whereas others have
been recognized for some time but can be viewed
afresh in light of emerging molecular data. Here we
discuss six of these recently described soft tissue
tumours.
Angiofibroma of Soft Tissue
In 2012, Mariño-Enriquez and Fletcher described 37
cases of a distinctive benign fibrovascular tumour
that arose most commonly as a soft tissue mass of
the extremities and was characterized by a specific
10

translocation t(5;8) (p15;q13). These lesions were
named as Angiofibroma of soft tissue. They are
slow growing tumours of the subcutis or deep soft
tissue most commonly arising in the extremities of
adults (median age 49 years) with a slight female
predominance (2:1). Most are well-circumscribed
lesions with a median size of 3.5 cm (range: 1.2–
12.0 cm).
Histologically, these tumours characterized by a
proliferation of uniform bland spindle cells with
present in a variably myxoid or collagenous stroma.
The cells have ovoid nuclei and inconspicuous
cytoplasm. A prominent network of small thin-walled
and finely branched blood vessels is seen. Epithelial
membrane antigen (EMA) is positive in nearly
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half of cases, usually only in scattered cells but
rarely diffusely. Focal staining for desmin, smooth
muscle actin (SMA), or CD34 may be seen in a
subset of cases, but S100 protein is negative. Main
differential diagnoses include Myxoid Liposarcoma,
Solitary Fibrous Tumour, Low grade fibromyxoid
Sarcoma, Low grade myxofibrosarcoma and cellular
angiofibroma. Angiofibroma of soft tissue is a benign
tumour, but may occasionally recur locally.

(WDL/ALT), Myxoid liposarcoma and Spindle cell
lipoma. Fortunately, molecular analysis can usually
easily exclude these possibilities.

Figure 1. Angiofibroma of soft tissue with chicken wire type vessels,
collagenous stroma and bland spindle cells

Figure 2. Fibrosarcoma-like lipomatous neoplasm exhibiting a wide
ranging of adipocytic differentiation (uni and bivacuolated lipoblasts)

Fibrosarcoma-like Lipomatous Neoplasm

Biphenotypic Sinonasal Sarcoma

In 2013, Deyrup and colleagues revisited the concept
of “spindle cell liposarcoma”. Based on their analysis
of previous publications on this topic, this term in
their opinion actually represents a heterogeneous
group of tumours, including variants of well
differentiated liposarcoma, myxoid liposarcoma, and
even spindle cell lipoma. Excluding those entities by
molecular analysis, they described 12 cases of a low
grade adipocytic neoplasm with prominent spindle
cell component which they termed “fibrosarcomalike lipomatous neoplasm” . Most of these tumours
arise in adults (mean age: 50 years). These tumours
present as superficial or deep soft tissue masses with
a wide size range (mean: 7.5 cm) arising in the groin
and para-testicular region, as well as the buttock,
thigh, flank, and shoulder.

Sarcomas arising in the sinonasal region are in
general very rare. Biphenotypic sinonasal sarcoma
a.k.a low-grade sinonasal sarcoma with neural
and myogenic features is a recently described
entity based on review of sinonasal sarcomas from
several decades of cases and consults. The clinical
presentation of biphenotypic sarcoma is features
of sinusitis, difficulty in breathing, facial pressure,
congestion, and, rarely, facial pain. The age range is
24 to 85 years (mean: 52 years), and there is female
predominance in the original series (21 women, 7
men). The tumour most commonly affects multiple
sites, including the nasal cavity proper (54 per cent)
and ethmoid sinus (57 per cent); extension into the
orbit and cribriform plate are common. The key
histologic features include poor circumscription,
infiltrative growth of highly cellular, bland spindle
cells, in vague “herringbone” pattern, without atypia
or frequent mitoses, along with benign proliferation
of respiratory epithelium with variable admixture
with tumor cells. These tumours show dual positivity
for S100 (neural marker) and Smooth muscle actin
and muscle specific actin (muscle markers), thus
called biphenotypic. A recent study by Wang and
colleagues found PAX3 rearrangement by FISH in
96 per cent of these cases (n=25); 79 per cent of
these cases were positive for PAX3-MAML3 fusion

Key histologic features include a uniform fibroblastlike spindle cells arranged in parallel bundles,
myxoid background with arborizing thin vessels,
wide range of lipoblasts lacking significant atypia,
including signet ring and spindled univacuolated/
bivacuolated cells. Univacuolated (“ice cream cone”)
and bivacuolated (“hourglass”) spindled lipoblasts
are often seen in fibrosarcoma-like lipomatous
neoplasm. Main Differential Diagnoses include Welldifferentiated liposarcoma/atypical lipomatous tumor

No recurrence or metastasis was identified in any
of these patients (mean follow-up time: 68 months;
range 9 month to 20 years), suggesting that perhaps
“liposarcoma” is not an appropriate term for this
tumor, based on current data.
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by RT-PCR. Main Differential Diagnoses include
Fibrosarcoma, Malignant peripheral nerve sheath
tumour and Monophasic Synovial sarcoma. Local
recurrence is common, but metastases or mortality
from disease have not yet been reported.

Figure 3. Biphenotypic sinonasal sarcoma showing fascicles of bland
spindle cells.

Malignant Gastrointestinal Neuroectodermal
Tumour
Malignant gastrointestinal neuroectodermal
tumor (GNET) is a rare, aggressive tumour of
the gastrointestinal (GI) tract that has previously
been called as “clear cell sarcoma-like tumour
of the GI tract with osteoclast-like giant cells”.
Stockman and colleagues proposed this name after
a review of 16 cases which showed histologic,
immunohistochemical, and molecular findings
similar to Clear cell sarcoma of soft tissue, but
with distinct differences, including no evidence
of melanocytic differentiation. GNET typically
arises in young to middle aged adults and most
often involves the small intestine. The tumour is
typically centered within the wall of the bowel,
with secondary involvement of the mucosa and
serosa. Histologically, the tumours grow in solid
sheets, pseudopapillary formations and alveolar
formations, generally without the well-formed
nests that characterize soft tissue-type clear cell
sarcoma. The cells are epithelioid to polygonal
with variable amount of eosinophilic cytoplasm
and vesicular nuclei with chromatin margination
and scattered intranuclear cytoplasmic inclusions.
The tumour cells are positive for S100, SOX10
and neuroendocrine markers; however, markers of
melanocytic differentiation, including Melan A and
HMB45 are negative. These tumours show EWSR1
rearrangement with numerous fusion partners. Main
differential diagnoses include GIST, monophasic
synovial sarcoma, melanoma, soft tissue clear cell
sarcoma and and Epithelioid Malignant Peripheral
Nerve Sheath tumour.
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Prognosis may be good if the tumour can be
completely removed; however, metastases are
common (over 50 per cent), often to liver and lymph
nodes.

Figure 4. Polygonal cells with a pseudovascular spaces seen in GNET.

Superficial CD34 Positive Fibroblastic Tumour
In 2013, Carter and colleagues described 18 cases
of a tumour with borderline malignant potential,
having unique characteristics i.e. striking nuclear
pleomorphism, paradoxically rare mitotic activity,
indolent behavior, and diffuse CD34 expression.
They termed it as “Superficial CD34 positive
fibroblastic tumour”. Awareness of this entity is
important, as there is a tendency for overdiagnosis as
a pleomorphic sarcoma in light of the nuclear atypia,
even though most cases do not recur or metastasize.
The tumour presents in adults as a slow-growing
supra-fascial mass with a mean size of 4.1 cm, most
commonly in the lower extremity. Histologically
it shows striking pleomorphism but low mitotic
rate (<1 per 50 HPFs). The cells are spindled to
epithelioid with abundant eosinophilic often granular
cytoplasm and are arranged into hypercellular
sheets or fascicles. Most tumour cells display
marked nuclear pleomorphism with hyperchromasia
and multiple large inclusion-like nucleoli as
well as cytoplasmic nuclear pseudoinclusions.
Xanthomatous foamy tumour cells are commonly
seen, and mixed inflammation is often present. There
is diffuse strong CD34 expression (always), focal
cytokeratin expression (often). FLI-1, ERG, S100
protein, desmin, smooth muscle actin, and TP53
are all negative, Ki-67 proliferative index is less
than one per cent, and nuclear INI-1 (SMARCB1)
expression is retained. Differential diagnoses
include Undifferentiated pleomorphic sarcoma,
Myxofibrosarcoma, Atypical fibroxanthoma,
Myxoinflammatory fibroblastic sarcoma and
Pleomorphic hyalinizing angiectactic tumor.
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Epithelioid Inflammatory Myofibroblastic
Sarcoma

predominantly neutrophils or lymphocytes is seen
intermixed with tumour cells. Immunohistochemical
stain for ALK protein shows positivity in unique
nuclear membrane or perinuclear cytoplasmic
pattern. The diagnosis of EIMS may be very
challenging given its rarity and lack of histologic
similarity to typical IMT. Main differential diagnoses
include Anaplastic large cell lymphoma (ALCL),
Epithelioid leiomyosarcoma, Rhabdomyosarcoma
and Dedifferentiated liposarcoma.

Figure 5. Large polygonal cells with glassy cytoplasm and prominent
nucleoli and rare mitosis; features seen in Superficial CD34 positive
fibroblastic tumour.

Inflammatory myofibroblastic tumour (IMT) is a
mesenchymal tumour of intermediate malignant
potential composed of spindled myofibroblasts with
admixed inflammation. A rare epithelioid variant
of IMT with distinctive nuclear membrane or
perinuclear ALK staining was recently described and
termed “epithelioid inflammatory myofibroblastic
sarcoma” (EIMS) in light of its more aggressive
behavior than conventional IMT. EIMS has a
marked male predominance and wide age range (7
months–63 years, median 39 years. These tumours
are almost exclusively found in the abdominal
cavity. The lesions range in size from 8 to 26 cm.
Histologically the tumors show epithelioid cells with
vesicular nuclei and prominent nucleoli present in
a myxoid stroma. Inflammatory infiltrate of either

Figure 6. Scattered epithelioid cells with abundant eosinophilic
cytoplasm, vesicular nuclei containing prominent nucleoli seen in
epithelioid inflammatory myofibroblastic sarcoma.

Conclusion
Owing to rapidly updating classification schemes
in histopathology, the pathologists as well as the
clinicians should be able to update their knowledge,
in order to be able to better understand the tumour
biology and therefore avoid over or under treatment
of patients.

A Snapshot of the Standards of Medical Care
-2017: American Diabetes Association Guidelines
Dr Sibtain Ahmed
Chemical Pathology

Diabetes Mellitus (DM) is one of the most widespread
diseases with an increasing incidence globally.
Statistically, Pakistan is ranked seventh among the
list of countries with a reportedly high prevalence
of DM making it a major public health concern. In
order to promote Diabetes care and management
every year the American Diabetes Association

(ADA) releases the Standards of Medical Care in
Diabetes. This document is the output of the ADA’s
multidisciplinary professional practice committee
that systematically searches MEDLINE to revise
or clarify recommendations. Feedback from the
larger clinical community is also incorporated. The
recommendations are summarized as follows:
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Diabetes Mellitus
Type 2

Latent Auto
Immune Diabetes of
Adults (LADA)

Maturity Onset
Diabetes of the Young
(MODY)

Gestational Diabetes
Mellitus (GDM)

Diabetes due to a
Diabetes due to
autoimmune B-cell progressive loss
destruction, usually of B-cell insulin
leading to absolute secretion frequently
insulin deficiency on the background
of insulin resistance

LADA is defined as
initially non-insulin
requiring diabetes
diagnosed in adults
with antibodies to
GAD - glutamic acid
decarboxylase.

MODY is an inherited
form of diabetes
mellitus. It is caused by
caused by mutations in
an autosomal dominant
gene disrupting insulin
production

Diabetes diagnosed
in the second or third
trimester of pregnancy
that is not clearly overt
diabetes

Individuals with a
To discriminate LADA
strong family history
from type I and/or type
of diabetes, presenting
II DM, diagnosis of
from the second to the
LADA has been based
fifth decade, should
on three criteria as given
be evaluated further
by The Immunology of
through sequencing
Diabetes Society:
of the suspected gene
• Adult age of onset
(HNF1A, GCK etc) and
(> 30 years of age);
detecting a mutation.
• Presence of at least
one circulating autoantibodies (GADA/ICA/
IAA/IA-2); and
• Initial insulin
independence (for the
first six months).

Perform a 75-g OGTT

Diabetes Mellitus
Type 1

Definitions

A1C ≥6.5%.
OR
FPG ≥126 mg/dL (7.0 mmol/L).

Diagnostic
Criteria

Age at
Diagnosis

OR
2-h PG ≥200 mg/dL (11.1 mmol/L)
during an OGTT.
OR
Random glucose ≥200 mg/dL (11.1
mmol/L).

Most commonly in Most commonly in
childhood
adults

Usually age ≥ 30 yrs

Criteria For Screening For Diabetes In Asymptomatic Adults
Testing should be considered in overweight or obese
(BMI ≥25 kg/m2 or ≥23 kg/m2 in Asian Americans)
adults who have one or more of the following risk
factors:
l
A1C ≥5.7% (39 mmol/mol), impaired glucose
tolerance, or impaired fasting glucose on previ
ous testing
l
First-degree relative with diabetes
l
High-risk race/ethnicity (e.g., African American,
Latino, NativeAmerican, Asian American,
Pacific Islander)
l
Women who were diagnosed with GDM
l
History of CVD
l
Hypertension (≥140/90 mmHg or on therapy for
hypertension)
l
HDL cholesterol level <35 mg/dL (0.90
mmol/L) and/or a triglyceride level >250 mg/dL
(2.82 mmol/L)
l
Women with polycystic ovary syndrome
l
Physical inactivity
l
Other clinical conditions associated with insulin
resistance (e.g. severe obesity, acanthosis
nigricans)
When to Screen? For all patients, testing should
begin at age 45 years.
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< 25 years

The diagnosis of GDM
is made when any of
the following plasma
glucose values are met
or exceeded:
• Fasting: 92 mg/dL
(5.1 mmol/L)
• 1 h: 180 mg/dL (10.0
mmol/L)
• 2 h: 153 mg/dL (8.5
mmol/L)

> 25 years

How often to screen? If results are normal, testing
should be repeated at a minimum of 3-year intervals,
with consideration of more frequent testing depending on initial results (e.g., those with prediabetes
should be tested yearly) and risk status.
Criteria For Screening For Diabetes In Asymptomatic Children
Overweight children (BMI >85th percentile for
age and sex, weight for height >85th percentile, or
weight >120% of ideal for height) plus with any two
of the following risk factors:
l
Family history of type 2 diabetes in first- or
second-degree relative
l
Race/ethnicity (Native American, African Ameri
can, Latino, Asian American, Pacific Islander)
l
Signs of insulin resistance or conditions
associated with insulin resistance (acanthosis
nigricans, hypertension, dyslipidemia, polycystic
ovary syndrome, or small-for-gestational-age
birth weight)
l
Maternal history of diabetes or GDM during the
child’s gestation
When to Screen? 10 years of age or at onset of puberty.
How often to screen? If results are normal, testing
should be repeated at a minimum of 3-year intervals.
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Criteria For Screening For GDM
An association between several maternal-fetal outcomes and the level of maternal hyperglycemia has
been reported hence screening for GDM is essential
in every pregnancy.
High risk group for GDM
l
Strong family history of diabetes
l
Prior history of GDM
l
Morbid obesity
l
Other manifestations of glucose intolerance
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How to Screen? 2-h Plasma Glucose after 75-g
OGTT
When to Screen?
l
At the 1st prenatal visit in those with risk factors.
l
At 24–28 weeks of gestation in women not
previously known to have diabetes.
l
Screen women with GDM for persistent diabetes
at 4–12 weeks postpartum, using the OGTT.
How often to screen? Women with GDM history
should have lifelong screening for development of
diabetes or pre-diabetes at least every 3 years.
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